SOLDESAM 8 mg/2 ml soluzione iniettabile
Sponsors
Fondazione European Myeloma Network Italy O.N.L.U.S., Ospedale San Raffaele S.r.l., European Myeloma Network B.V., Ceska Myelomova Skupina z.s., Emn Trial Office S.r.l. Impresa Sociale, Emn Trial Office S.r.l. Impresa Sociale
Conditions
Adult patients with indication of arthroscopic anterior cruciate ligament reconstructionMultiple Myeloma relapsed and/or refractoryRelapsed Multiple MyelomaYOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLS
Phase 2
Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]
Active, not recruitingCTIS2023-506733-30-00
Start: 2019-05-16Target: 45Updated: 2025-07-15
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation
Active, not recruitingCTIS2024-511781-37-00
Start: 2019-04-16Target: 401Updated: 2025-11-26
Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel study)
Active, not recruitingCTIS2024-513397-21-00
Start: 2021-09-16Target: 25Updated: 2025-10-27
MELFLUFEN FOR ELDERLY MYELOMA PATIENTS IN SECOND OR SUBSEQUENT RELAPSE (MELISSA)
WithdrawnCTIS2024-514652-33-00
Target: 30Updated: 2025-02-12